Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma

Who May Qualify: - Oral and written willing to sign a consent form (IC) - Aged 18 years and older - Fit for both organ-sparing surgery and colectomy - Pathologically confirmed T1-2 adenocarcinoma of the colon following R0, R1, or Rx endoscopic resection with an estimated LNM risk \>15% (Table 5.2.2. in module 5.2 of the Dutch CRC guideline); or a lesion macroscopically suspected to be (deep-invasive) T1 colon cancer, measuring \<40 mm, for which wedge resection is considered the most suitable local resection technique as recommended by the MDT - The resection scar after local excision is expected to be clearly recognized at endoscopy, either by a tattoo or by detecting a scar in the colorectal segment where no other polypectomies were performed - Lesion located \>25cm from the anus based on endoscopic measurement, or above sigmoid take-off Who Should NOT Join This Trial: - Patients who opt for active follow-up instead of surgery following shared decision-making - Distant metastasis - Lynch syndrome - Another active malignancy requiring palliative treatment at the time of colon cancer diagnosis - Previous colorectal cancer within the last 5 years - Tumours that comprised \>50% of the colon circumference before resection - Tumours involving the ileocaecal valve - Pregnancy, lactation or a planned pregnancy during the course of the study - Known allergy to any of the compounds used for SLN identification (ICG, Iodine or Sodium iodide) - Previous colonic surgery (excluding appendectomy) - Contra-indication for laparoscopic or robotic surgery - Severe kidney- or liver failure - Hyperthyroidism or an autonomously functioning thyroid adenoma Always talk to your doctor about whether this trial is right for you.